Market analysts appear to have hugely underestimated the EPS dilution from the Theiss 50% sale. Leighton now goes in the DOG box with QBE.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%